Replimune (REPL) Share-based Compensation (2017 - 2025)
Replimune's (REPL) quarterly Share-based Compensation came in at $7.0 million in Q4 2025, down 18.43% year-on-year from $8.6 million in Q4 2024, and down 15.48% quarter-over-quarter from $8.3 million in Q3 2025.
Replimune (REPL) Share-based Compensation (2017 - 2025) Analysis & Trends
Replimune has disclosed Share-based Compensation across 9 years of filings, most recently posting $7.0 million for Q4 2025.
- Share-based Compensation for Q4 2025 came in at $7.0 million, down 18.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $32.4 million (down 6.52% YoY), and the FY2025 annual result was $35.0 million, up 2.69% from the prior year.
- Share-based Compensation came in at $7.0 million for Q4 2025 at Replimune, down from $8.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $9.5 million in Q2 2024 to a low of $3.5 million in Q1 2021.
- The 5-year median for Share-based Compensation is $7.6 million (2022), against an average of $7.5 million.
- Across the five-year window, Share-based Compensation surged 153.24% in 2021 and dropped 18.43% in 2025, its largest moves.
- Replimune's Share-based Compensation stood at $5.9 million in 2021, then grew by 18.67% to $7.0 million in 2022, then increased by 17.33% to $8.2 million in 2023, then advanced by 4.84% to $8.6 million in 2024, then decreased by 18.43% to $7.0 million in 2025.
- The last three Share-based Compensation figures came in at $7.0 million (Q4 2025), $8.3 million (Q3 2025), and $8.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 26.47 Mn |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | 7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.05 Mn |
| Dec 31, 2025 | 7.05 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Jun 30, 2025 | 8.76 Mn |
| Jun 30, 2025 | 8.76 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Dec 31, 2024 | 8.64 Mn |
| Dec 31, 2024 | 8.64 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Mar 31, 2024 | 7.92 Mn |
| Mar 31, 2024 | 7.92 Mn |
| Dec 31, 2023 | 8.24 Mn |
| Dec 31, 2023 | 8.24 Mn |
| Sep 30, 2023 | 9.12 Mn |
| Sep 30, 2023 | 9.12 Mn |